FDA Sounds the Alarm on 7-OH: The Hidden Opioid Risk in Kratom Products

Could a compound hiding in kratom products be the next opioid crisis waiting to happen?

The FDA has set its sights on 7-hydroxymitragynine, a powerful kratom byproduct it says poses a serious threat to public health.1 For healthcare professionals, this increased regulatory focus also raises the possibility of state board scrutiny, particularly for those working in pharmacies, clinics, wellness centers, or practices where dietary supplements may be sold, recommended, or discussed with patients.

KEY POINTS

• The FDA recommends classifying concentrated 7-OH products as Schedule I under the Controlled Substances Act.
• FDA warning letters were issued to companies marketing unlawful 7-OH supplements, tablets, gummies, and beverages.
• Florida enacted emergency rules banning concentrated 7-OH and requiring disclosure of its content in kratom products.
• Healthcare professionals handling 7-OH products risk regulatory exposure, licensing inquiries, and potential board scrutiny

What Is 7-Hydroxymitragynine (7-OH)? 

Pharmacology, Potency & Regulatory Concerns

7-Hydroxymitragynine, commonly abbreviated as 7-OH, is a psychoactive alkaloid that occurs naturally in the kratom plant.1,2 Pharmacologically, 7-OH acts as a partial agonist at the μ-opioid receptor, causing pronounced opioid-like effects; approximately 13 times and 46 times more potent than morphine and mitragynine (the primary alkaloid in kratom), respectively.[1]

The public health concern arises because synthetic and concentrated 7-OH products are increasingly appearing on the U.S. market. These products are often sold online, in gas stations, and in convenience stores, frequently marketed as dietary supplements or “natural” alternatives while concealing their opioid- like risks.[3] As these products become more common, healthcare providers may encounter patients using them, creating documentation, counseling, and safety considerations that can become relevant during a licensing or gulatory investigation if harm occurs.

Recent FDA investigations found 7-OH incorporated into capsules, powders, and liquids promoted for pain relief, energy, or relaxation. In some cases, products were labeled as kratom extracts but contained unnaturally high concentrations of 7-OH (levels far exceeding what would occur in nature).[1]

This surge in synthetic formulations highlights the urgency of action. Without stronger oversight, concentrated 7-OH products could follow the trajectory of past opioid crises, creating not only serious public health risks but also prompting regulatory action.[1] For pharmacists and clinicians, knowingly or unknowingly handling misbranded or unapproved products can expose them to allegations of unprofessional conduct, record-keeping violations, or failure to meet expected standards of care.

FDA Enforcement Actions & Schedule Recommendations for 7-OH

On July 29, 2025, the FDA recommended that concentrated 7-OH products be classified as Schedule I under the Controlled Substances Act, citing its high potential for abuse and lack of approved medical use. That announcement also clarified that natural kratom leaf products are not the target of this scheduling push, but rather synthetic or highly concentrated 7-OH forms.[1],[2]

Alongside the recommendation, the FDA issued seven warning letters to companies illegally marketing 7- OH formulations such as tablets, gummies, drink mixes, and “shots,” emphasizing that 7-OH is not lawful in dietary supplements or conventional foods.[3]

Historically, FDA warning letters  often lead to parallel actions by state boards of pharmacy and medicine, which means licensed professionals connected to facilities selling prohibited substances may face heightened scrutiny or mandatory inquiries. Even indirect involvement, through documentation lapses, product placement, or counseling notes, can be cited during a board review.

State-Level Responses: Bans, Labeling Rules & Controlled Substance Scheduling

Florida moved quickly. The state’s Attorney General enacted an emergency rule placing concentrated forms of 7-OH into Schedule I, making their sale, possession, or distribution illegal under state law.[4] One month later, Agriculture Commissioner Wilton Simpson issued an additional rule requiring retailers to disclose the amount of 7-OH in each kratom product sold.[5]

Florida’s swift action highlights a broader patchwork nationwide. According to Stateline, more than half of U.S. states and D.C. have enacted some form of kratom regulation, from outright bans in places like Alabama and Indiana to labeling and age restrictions elsewhere, while other states still allow sales of concentrated or synthetic 7-OH in gas stations and smoke shops.[6]

This inconsistent regulatory landscape increases the risk of unintentional violations, especially for providers practicing telehealth, working near state borders, or selling supplements in multiple jurisdictions.

Regulation on the Horizon: Future Regulatory Outlook for 7-OH

With federal scheduling still pending, the lack of consistent oversight leaves consumers vulnerable. Even so, the momentum is unmistakable: the crackdown on 7-OH reflects a broader shift in how regulators confront emerging substances marketed as dietary supplements. Increasingly, it appears that lawmakers are finally placing consumer safety and public health back at the center of the conversation. For healthcare professionals, this evolving landscape makes it essential to maintain careful documentation, confirm supplement legality, and address any state board inquiries promptly to reduce the risk of escalating licensing concerns.

Early guidance can help prevent documentation issues or product-related misunderstandings from escalating into licensing actions. Boesen & Snow represents healthcare professionals facing state board reviews, compliance questions, or regulatory concerns involving supplements like 7-OH.

FREQUENTLY ASKED QUESTIONS

What is 7-hydroxymitragynine (7-OH) and why is it dangerous?

7-OH is a potent alkaloid found in kratom with opioid-like effects. Synthetic or concentrated forms are far stronger than natural kratom and carry a high risk of abuse, overdose, and public health harm.

Are natural kratom products legal under federal law?

Yes. The FDA’s scheduling recommendation specifically targets synthetic or highly concentrated 7-OH products. Whole-leaf kratom is not currently classified as a controlled substance federally.

How does FDA enforcement affect healthcare professionals?

Pharmacists, clinicians, and wellness providers handling misbranded or unapproved 7-OH products may face state board investigations, marketing and documentation inquiries , or licensing reviews.

What should healthcare providers do if a patient reports using 7-OH products?

Providers should document usage carefully, counsel on risks, and avoid recommending or dispensing synthetic 7-OH. Proper record-keeping can help reduce regulatory exposure.

How can pharmacies and healthcare businesses ensure compliance?

Regularly review FDA updates, implement strict documentation policies, verify supplement legality, and consult legal counsel experienced in healthcare law and regulatory compliance.

References:

1. Reissig CJ, Chiapperino D, Seitz A, et al. 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat. U.S. Food and Drug Administration. Published July 29, 2025.
2. U.S. Food and Drug Administration. FDA takes steps to restrict 7-OH opioid products threatening American consumers. FDA. Published July 29, 2025. 
3. U.S. Food and Drug Administration. Warning letters issued to firms marketing products containing 7- hydroxymitragynine (7-OH). FDA News Release; July 15, 2025. Published July 15, 2025.
4.  U.S. Food and Drug Administration. Statement from FDA Commissioner Martin Makary, MD, MPH, on Florida restriction of 7-OH opioid products. FDA. Published August 13, 2025.

5. Caputo L. ‘Gas station morphine’: Florida to issue emergency labeling rule for kratom compound 7-OH. Florida Phoenix. Published September 18, 2025. 
6. Stateline. Kratom faces increasing scrutiny from states and the feds. Pew Charitable Trusts. Published August 11, 2025.